{"id":307716,"date":"2026-10-14T13:01:28","date_gmt":"2026-10-14T07:31:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=307716"},"modified":"2026-10-14T13:01:28","modified_gmt":"2026-10-14T07:31:28","slug":"contract-manufacturing-hydration-formulation-and-life-science-service-stocks-roadmap-watch-guide","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/contract-manufacturing-hydration-formulation-and-life-science-service-stocks-roadmap-watch-guide\/","title":{"rendered":"3 Contract Manufacturing, Hydration Formulation and Life Science Service Stocks With a Strong Future Roadmap: Akums Drugs and Pharmaceuticals, FDC and Indegene"},"content":{"rendered":"

Akums Rs 769.30, P\/E 42.26. FDC Rs 338.45, P\/E 18.05. Indegene Rs 580.70, P\/E 35.20. Closing prices of 13 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Contract manufacturing, hydration formulation and life science service stocks with the clearest long-term roadmaps today include Akums in contract development and manufacturing of pharmaceutical and nutraceutical products, FDC in oral rehydration products, ophthalmic and other branded formulations and Indegene in commercial, medical and regulatory services for life science companies. FY26 revenue growth was 7.6% at Akums, 3.9% at FDC and 21.6% at Indegene. P\/E stands at 42.26 for Akums (industry 37.59), 18.05 for FDC (industry 37.59) and 35.20 for Indegene (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Contract manufacturing, hydration formulation and life science service stocks give investors exposure to medicines and services that drug brands, doctors and patients rely on. Contract orders, prescription growth and client wins decide how much of that demand turns into profit.<\/p>\n

This list covers three contract manufacturing, hydration formulation and life science service stocks: Akums Drugs and Pharmaceuticals for contract development and manufacturing of pharmaceutical and nutraceutical products, FDC for oral rehydration products, ophthalmic and other branded formulations and Indegene for commercial, medical and regulatory services for life science companies. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n